Abdulrahman Al-Mashdali: Targeted Therapies for CNS Involvement in CLL
Abdulrahman Al-Mashdali, Hematology Chief Fellow at Hamad Medical Corporation, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Therapeutic Advances in Hematology, adding:
”I’m pleased to share our newly published systematic review in Therapeutic Advances in Hematology:
‘Novel targeted therapies for central nervous system involvement in chronic lymphocytic leukemia: A systematic review.’
CNS involvement in CLL/SLL is rare, diagnostically challenging, and historically associated with poor outcomes. In this systematic review, we analyzed 26 studies including 32 patients treated with novel targeted therapies.
Key findings:
- 94.1 percent overall response rate across 34 treatment regimens
- 55.9 percent complete responses and 38.2 percent partial responses
- Ibrutinib was the most frequently used targeted agent
- Venetoclax and ibrutinib–venetoclax combinations demonstrated encouraging activity
- Responses were observed even in patients with adverse biological features such as TP53 abnormalities, del(17p), and unmutated IGHV
While these findings are encouraging, the evidence remains largely based on case reports and small series. Prospective multicenter studies are needed to better define treatment sequencing, combination strategies, and the role of intrathecal therapy and radiotherapy.
I’m grateful to all my co-authors and colleagues who contributed to this work.”
Title: Novel targeted therapies for central nervous system involvement in chronic lymphocytic leukemia: A systematic review
Authors: Abdulrahman F. Al-Mashdali, Mujahid O. Abdelraof, Raga M. Mukhtar, Shehab F. Mohamed,
Stay updated with Hemostasis Today.
-
Aug 23, 2026, 17:51Gurpreet Kaurr: A Proud Milestone in Haematology and Oncology
-
Aug 23, 2026, 17:33Kathrine Kaspersen: How Voluntary Plasma Donors Helped Transform Denmark’s Plasma Supply
-
Aug 23, 2026, 16:51Sthanu Subramanian: Empagliflozin and a Rise in Hematocrit
-
Aug 23, 2026, 16:50Lale Tokgözoğlu: New PCSK9i Research Published in the European Heart Journal
-
Aug 23, 2026, 16:44Eric Gehrie: Your 2026 Guide to the Essentials of Transfusion Medicine
-
Aug 23, 2026, 16:35Thomas Dayspring: The Overlooked Pathway in Cholesterol Homeostasis
-
Aug 23, 2026, 16:28Evan Mapelu: The People Who Make Cancer Care Meaningful
-
Aug 23, 2026, 16:09Felice Gragnano: New Publication on Aspirin Discontinuation After PCI for Acute Coronary Syndromes
-
Aug 23, 2026, 16:06Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia